AzTrials
AzTrials

Lymphoma, Non-HodgkinPhase 2CAPTURNCT03297606

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

A Phase 2 study testing Olaparib, Dasatinib and Nivolumab plus Ipilimumab in people with Lymphoma, Non-Hodgkin and Multiple Myeloma, run by Canadian Cancer Trials Group at 10 sites in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Olaparib, Dasatinib and Nivolumab plus Ipilimumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
720 participants
Where
10 sitesCanada
Study dates
23 Mar 2018to 31 Jan 2027
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known to prolong life, or who has refused such treatment.
  • ECOG performance status 0-2.
  • Patients must have normal organ function as follows:
  • Absolute neutrophil count: ≥ 1.5 x 10^9/L for solid tumours; ≥ 1.0 x 10^9/L for neurologic malignancies
  • Platelets ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow involvement by myeloma or lymphoma).
  • Total bilirubin ≤ 1.5 x UNL.
Show all 13Show fewer
  • AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless liver metastases are present in which case they must be < 5 x ULN;
  • Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥ 50mg/min/1.73µ^2
  • Patients must have measurable disease
  • Results must be available from tumour genomic or protein expression testing (if used to identify genetic variants), from one of the initiatives / groups listed in protocol Appendix VII. The test may have been performed on the primary tumour or a metastatic deposit (including bone marrow), or blood, in a diagnostic or research laboratory and must reveal a potentially actionable variant.
  • Patient consent (Main Study Consent for the screening step) must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to the screening step to document their willingness to participate
  • Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre or a CCTG IND site. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.
  • Women/men of childbearing potential must have agreed to use a highly effective contraceptive method.

Who cannot join

  • Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.
  • Patients with ongoing toxicity ≥ CTCAE grade 2, other than peripheral neuropathy or asymptomatic, corrected biochemical toxicities (e.g. hypothyroidism corrected by thyroid replacement), related to prior anti-tumour treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.
  • Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g. megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate cancer. These medications must have been started ≥ one month prior to enrollment on this study. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility criteria.
  • Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within one month prior to screening. All patients with previously treated brain metastases must be stable (clinically and radiologically) for at least one month after completion of treatment and either off steroid treatment or only taking physiological doses of steroids prior to the screening step.
  • Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.
  • Patients with known left ventricular ejection fraction (LVEF) < 40%.
Show all 11Show fewer
  • Patients with stroke (including TIA) or acute myocardial infarction within three months prior to the screening step.
  • Patients with acute gastrointestinal bleeding within one month prior to the screening step.
  • Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
  • Lactating and nursing women
  • Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician.

Trial locations and contacts

10 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Janet Dancey contact

613-533-6430

jdancey@ctg.queensu.ca

10 sites in 1 country

Canada10 sites, 10 recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2

    Quincy Chu, 780 432-8248

    Recruiting

  • BCCA - Kelowna

    Kelowna, British Columbia, V1Y 5L3

    Sara Kristina Taylor, 250 712-3996

    Recruiting

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7

    Francisco Vera-Badillo

    Recruiting

  • London Health Sciences Centre Research Inc.

    London, Ontario, N6A 5W9

    Stephen Welch, 519 685-8640

    Recruiting

  • The Jewish General Hospital

    Montreal, Quebec, H3T 1E2

    Cristiano Ferrario, 514 398-8307

    Recruiting

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6

    John Hilton, 613 737-7700 ext. 75086

    Recruiting

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1

    Kimberly Hagel, 306 766-2691

    Recruiting

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, S7N 4H4

    Sunil K. Yadav, 306 655-2710

    Recruiting

  • University Health Network

    Toronto, Ontario, M5G 2M9

    Lillian Siu, 416 946-2911

    Recruiting

  • BCCA - Vancouver

    Vancouver, British Columbia, V5Z 4E6

    Daniel John Renouf, 604 877-6000 ext. 672357

    Recruiting

Other trials in Canada

About this study

Official title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Read the detailed description

Recent advances in laboratory technology have enabled the identification of changes in the genetic makeup of tumors that might be responsible for their malignant behavior such as uncontrolled growth and spread. Some of these changes can be 'druggable', i.e. there may be cancer medicines that can specifically act on the tumour's genetic abnormality. Several cancer centers and programs have initiated this type of molecular profiling across Canada, with the goal to identify 'druggable' changes in tumors to find matching therapy for patients. These include initiatives in British Columbia, Ontario and Quebec. The CAnadian Profiling and Targeted agent Utilization tRial (CAPTUR) will test the activity of a list of commercially available targeted agents in patients who have undergone tumor profiling and have 'druggable' changes identified in their cancers.

Being tested
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib
Medical subject headings
Lymphoma, Non-Hodgkin, Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OlaparibDrug

    300mg taken twice daily

  • DasatinibDrug

    100mg administered orally once daily

  • Nivolumab plus IpilimumabDrug

    • Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.
    • Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

  • AxitinibDrug

    5mg orally twice daily

  • BosutinibDrug

    500mg orally once daily

  • CrizotinibDrug

    250mg orally twice daily

  • PalbociclibDrug

    125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

  • SunitinibDrug

    50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

  • TemsirolimusDrug

    25mg infused over a 30-60 minute period once a week

  • ErlotinibDrug

    150mg orally, once daily

  • Trastuzumab plus PertuzumabDrug

    Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.

    Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

  • Vemurafenib plus CobimetinibDrug

    Vemurafenib = 960 mg orally every 12 hours.

    Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

  • VismodegibDrug

    150mg taken orally, once daily

  • TucatinibDrug

    300mg taken orally, twice daily

Study groups in NCT03297606
Study groupRoleWhat they receive
Group 1 - Arm CLOSED, no patients recruitedExperimentalVEGFR1, VEGFR2, VEGFR3
Receives: Drug: Axitinib
Group 2 - Arm CLOSED, no patients recruitedExperimentalBCR-ABL, SRC
Receives: Drug: Bosutinib
Group 3 - Arm CLOSEDExperimentalALK, ROS1, MET
Receives: Drug: Crizotinib
Group 4 - Arm CLOSED, no patients recruitedExperimentalKIT, PDGFRA, PDGFRB, ABL1
Receives: Drug: Dasatinib
Group 5 - Arm CLOSEDExperimentalEGFR
Receives: Drug: Erlotinib
Group 6 - Arm CLOSEDExperimentalhigh mutation burden, POLE, POLD1
Receives: Drug: Nivolumab plus Ipilimumab
Group 7 - Arm CLOSEDExperimentalBRCA1, BRCA2, mutations in HRD
Receives: Drug: Olaparib
Group 8 - Arm CLOSEDExperimentalCDKN2A, CDK4, CCND1, SMARCA4
Receives: Drug: Palbociclib
Group 9 Arm CLOSEDExperimentalCSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL
Receives: Drug: Sunitinib
Group 10 Arm CLOSEDExperimentalAKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2
Receives: Drug: Temsirolimus
Group 11 - Arm CLOSEDExperimentalERBB2
Receives: Drug: Trastuzumab plus Pertuzumab
Group 12 - Arm CLOSEDExperimentalBRAFV600
Receives: Drug: Vemurafenib plus Cobimetinib
Group 13 - Arm CLOSEDExperimentalPTCH1, SMO
Receives: Drug: Vismodegib
Group 14ExperimentalERBB2
Receives: Drug: Tucatinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response rate defined as the number of patients with complete response or partial response

    over the total number of patients in a given cohort.

    Measured: 4 years

Secondary outcomes (2)

  1. Number and severity of adverse events grade >3, or of lesser grade resulting in discontinuation, delay or reduction in dose of study drug

    measured by CTCAE

    Measured: 4 years

  2. Progression-free survival by disease-appropriate objective criteria

    Measured: 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Sep 2017
  2. Study start23 Mar 2018
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
720 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03297606
Sponsor's protocol ID
PM1
Other IDs
ESR-17-12831, CA209-9DL, ML39800, WI233446
Acronym
CAPTUR
Status last verified
Mar 2026
First submitted
27 Sep 2017
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Olaparib, Dasatinib and Nivolumab plus Ipilimumab in people with Lymphoma, Non-Hodgkin and Multiple Myeloma, run by Canadian Cancer Trials Group at 10 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Janet Dancey (613-533-6430, jdancey@ctg.queensu.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective response rate defined as the number of patients with complete response or partial response (time frame: 4 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03297606.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in